2026-03-11T03:37:38Z
https://hiroshima.repo.nii.ac.jp/oai
oai:hiroshima.repo.nii.ac.jp:02013831
2025-06-02T03:36:43Z
1727147343679:1730442224523:1739272051658
Clinical utility of Duke pancreatic monoclonal antigen type 2 in resectable biliary tract cancers
SUMIYOSHI, Tatsuaki
SUMIYOSHI
Tatsuaki
UEMURA, Kenichirou
UEMURA
Kenichirou
SHINTAKUYA, Ryuta
SHINTAKUYA
Ryuta
OKADA, Kenjiro
OKADA
Kenjiro
BABA, Kenta
BABA
Kenta
HARADA, Takumi
HARADA
Takumi
NAKAMURA, Shinya
NAKAMURA
Shinya
MURAKAMI, Yoshiaki
MURAKAMI
Yoshiaki
ARIHIRO, Koji
ARIHIRO
Koji
ISHII, Yasutaka
ISHII
Yasutaka
OKA, Shiro
OKA
Shiro
TAKAHASHI, Shinya
TAKAHASHI
Shinya
open access
Copyright (c) 2024 Hiroshima University Medical Press
biliary tract cancer
duke pancreatic monoclonal antigen type 2
carbohydrate antigen 19-9
This study aimed to investigate the clinical utility of Duke pancreatic monoclonal antigen type 2 (DUPAN-2) in addition to carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic Antigen (CEA) in biliary tract cancers (BTCs). Patients who underwent surgery for BTC were investigated. BTCs included five types: intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma (HC), distal cholangiocarcinoma (DC), gall bladder carcinoma (GBC), and ampullary carcinoma (AC). The percentages of patients with elevated and normal tumor marker levels (high and normal groups) were determined across five BTC types, and recurrence-free survivals (RFSs) were compared between the two groups. Forty, 67, 56, 51, and 51 patients had ICC, HC, DC, GBC, and AC, respectively. In all patients, the percentages of patients with elevated tumor marker levels decreased in the order of CA19-9 (44.9%), DUPAN-2 (36.6%), and CEA (17.0%). This trend was consistent across four cancer types: ICC, HC, DC and GBC. In all patients, the high groups in three markers exhibited significantly poorer RFSs compared to the normal groups (P < 0.01, P < 0.01, P < 0.01, respectively). DUPAN-2 is a useful marker for recurrence in patients with resectable BTC.
Hiroshima University Medical Press
2024-12
eng
departmental bulletin paper
VoR
https://hiroshima.repo.nii.ac.jp/records/2013831
Hiroshima Journal of Medical Sciences
73
3-4
35
35
39
https://hiroshima.repo.nii.ac.jp/record/2013831/files/HiroshimaJMedSci_73_35.pdf
1.4 MB